CA2352454C - Peptide-based vaccine for influenza - Google Patents
Peptide-based vaccine for influenza Download PDFInfo
- Publication number
- CA2352454C CA2352454C CA2352454A CA2352454A CA2352454C CA 2352454 C CA2352454 C CA 2352454C CA 2352454 A CA2352454 A CA 2352454A CA 2352454 A CA2352454 A CA 2352454A CA 2352454 C CA2352454 C CA 2352454C
- Authority
- CA
- Canada
- Prior art keywords
- human
- influenza
- epitopes
- epitope
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010022000 influenza Diseases 0.000 title claims description 48
- 229940023041 peptide vaccine Drugs 0.000 title description 9
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 48
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 48
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 48
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 48
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 47
- 108010061100 Nucleoproteins Proteins 0.000 claims abstract description 43
- 102000011931 Nucleoproteins Human genes 0.000 claims abstract description 43
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 28
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 17
- 229960003971 influenza vaccine Drugs 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 23
- 230000028993 immune response Effects 0.000 claims description 6
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 3
- 108010040721 Flagellin Proteins 0.000 abstract description 29
- 210000003495 flagella Anatomy 0.000 abstract description 20
- 210000004698 lymphocyte Anatomy 0.000 abstract description 15
- 210000005260 human cell Anatomy 0.000 abstract description 12
- 241000607142 Salmonella Species 0.000 abstract description 6
- 108060003393 Granulin Proteins 0.000 abstract description 3
- 230000001472 cytotoxic effect Effects 0.000 abstract description 3
- 231100000433 cytotoxic Toxicity 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 57
- 241000700605 Viruses Species 0.000 description 30
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 230000003053 immunization Effects 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 210000004072 lung Anatomy 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 20
- 229960005486 vaccine Drugs 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 230000005855 radiation Effects 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 230000001665 lethal effect Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 231100000636 lethal dose Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000027645 antigenic variation Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 230000007108 local immune response Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 229940124842 Salmonella vaccine Drugs 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 241000512294 Thais Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 108010075326 HLA-B51 Antigen Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 101900222562 Influenza A virus Nucleoprotein Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000006833 oxoid nutrient broth Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12733198A IL127331A0 (en) | 1998-11-30 | 1998-11-30 | Peptide-based vaccine for influenza |
| IL127331 | 1998-11-30 | ||
| PCT/IL1999/000640 WO2000032228A2 (en) | 1998-11-30 | 1999-11-28 | Peptide-based vaccine for influenza |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2352454A1 CA2352454A1 (en) | 2000-06-08 |
| CA2352454C true CA2352454C (en) | 2013-02-05 |
Family
ID=11072200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2352454A Expired - Lifetime CA2352454C (en) | 1998-11-30 | 1999-11-28 | Peptide-based vaccine for influenza |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6740325B1 (enExample) |
| EP (2) | EP1135159A2 (enExample) |
| JP (1) | JP2002531415A (enExample) |
| KR (1) | KR100703571B1 (enExample) |
| AT (1) | ATE556719T1 (enExample) |
| AU (1) | AU766883B2 (enExample) |
| BR (1) | BR9915811A (enExample) |
| CA (1) | CA2352454C (enExample) |
| DK (1) | DK2204187T3 (enExample) |
| ES (1) | ES2389611T3 (enExample) |
| HK (1) | HK1040620A1 (enExample) |
| IL (3) | IL127331A0 (enExample) |
| NZ (1) | NZ511918A (enExample) |
| PT (1) | PT2204187E (enExample) |
| WO (1) | WO2000032228A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127331A0 (en) * | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
| AU2002223398A1 (en) * | 2000-08-10 | 2002-04-08 | Tsinghua University | A vaccine for influenza virus and its preparation |
| FI20031536A0 (fi) * | 2003-10-20 | 2003-10-20 | Biotie Therapies Oyj | Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen |
| DK1692265T3 (da) | 2003-11-04 | 2011-11-21 | Univ Tulane | Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner |
| GB0716992D0 (en) * | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
| WO2006074303A2 (en) * | 2005-01-05 | 2006-07-13 | Philadelphia Health And Education Corporation | Delivery vehicles, bioactive substances and viral vaccines |
| MY157941A (en) | 2005-01-19 | 2016-08-15 | Vaxinnate Corp | Compositions of pathogen-associated molecular patterns and methods of use |
| FI20060200A0 (fi) * | 2005-04-20 | 2006-02-27 | Glykos Finland Oy | Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi |
| MX2007015105A (es) * | 2005-06-01 | 2008-03-18 | Variation Biotechnologies Inc | Formulacion de vacuna de influenza a base de peptido. |
| US7871626B2 (en) * | 2005-08-04 | 2011-01-18 | St. Jude Children's Research Hospital | Modified influenza virus for monitoring and improving vaccine efficiency |
| US7468187B2 (en) * | 2005-10-18 | 2008-12-23 | Iowa State University Research Foundation, Inc. | Canine influenza virus and related compositions and methods of use |
| WO2007051036A2 (en) * | 2005-10-26 | 2007-05-03 | Protelix, Inc. | Influenza combinatorial antigen vaccine |
| US9533036B2 (en) * | 2005-11-07 | 2017-01-03 | Microvax, Llc | Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein |
| AU2006322907B2 (en) * | 2005-12-06 | 2012-08-02 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved influenza vaccine |
| HUE049580T2 (hu) * | 2006-01-27 | 2020-09-28 | Seqirus Uk Ltd | Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok |
| GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
| ES2534332T3 (es) * | 2006-03-07 | 2015-04-21 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| US20080208486A1 (en) * | 2006-03-23 | 2008-08-28 | Jari Natunen | Integrated System, Device and Use Thereof |
| US8222204B2 (en) | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
| WO2008002663A2 (en) * | 2006-06-28 | 2008-01-03 | The Board Of Trustees Of The Leland Stanford Junior University | Immunogenic protein constructs |
| FI20060946A0 (fi) * | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
| EP2139908A4 (en) | 2007-03-12 | 2011-02-16 | Antigen Express Inc | REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY |
| JP5654345B2 (ja) | 2007-08-02 | 2015-01-14 | ビオンドヴァックス ファーマシューティカルズ リミテッド | 多量体マルチエピトープインフルエンザワクチン |
| CA2721246A1 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
| CA2721800A1 (en) | 2008-04-21 | 2009-10-29 | Nanobio Corporation | Nanoemulsion influenza vaccine |
| JP2011519834A (ja) * | 2008-04-25 | 2011-07-14 | インスティチュート フォー システムズ バイオロジー | フラジェリンポリペプチドワクチン |
| WO2009135152A2 (en) | 2008-05-02 | 2009-11-05 | University Of Rochester | Arrayed detector system for measurement of influenza immune response |
| WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
| WO2011005772A1 (en) | 2009-07-06 | 2011-01-13 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| ES2573427T3 (es) | 2009-07-06 | 2016-06-07 | Variation Biotechnologies Inc. | Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas |
| CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
| WO2012097346A1 (en) | 2011-01-13 | 2012-07-19 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
| CN107296792B (zh) | 2011-01-13 | 2021-07-27 | 变异生物技术公司 | 囊泡及由其产生之制剂的制备方法 |
| WO2012114323A1 (en) | 2011-02-22 | 2012-08-30 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
| CA2840982C (en) | 2011-07-06 | 2022-06-07 | Vira BITKO | Human respiratory syncytial virus vaccine |
| WO2013028738A1 (en) | 2011-08-22 | 2013-02-28 | Nanobio Corporation | Herpes simplex virus nanoemulsion vaccine |
| EP2780350B1 (en) | 2011-11-18 | 2019-03-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
| CA2894442C (en) | 2012-01-12 | 2020-01-21 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
| US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| KR20140099828A (ko) | 2013-02-05 | 2014-08-13 | 닛토덴코 가부시키가이샤 | 점막 투여용 백신 조성물 |
| EP2762152A1 (en) | 2013-02-05 | 2014-08-06 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
| CN103961306A (zh) | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | 经皮给予用疫苗组合物 |
| EP3662927A3 (en) | 2013-02-05 | 2020-10-21 | Nitto Denko Corporation | Vaccine composition |
| RU2697443C2 (ru) | 2013-02-05 | 2019-08-14 | Нитто Денко Корпорейшн | Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения |
| US10206985B2 (en) | 2013-02-05 | 2019-02-19 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for mucosal administration |
| RU2014102948A (ru) * | 2013-02-05 | 2015-08-10 | Нитто Денко Корпорейшн | Вакцинная композиция для мукозального введения |
| CN103961698A (zh) | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | 经皮或粘膜给予用疫苗组合物 |
| CA2841016A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for transdermal administration |
| US20140220100A1 (en) | 2013-02-05 | 2014-08-07 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
| RU2531235C2 (ru) | 2013-02-15 | 2014-10-20 | Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") | Поливалентная вакцина против гриппа на основе гибридного белка |
| CN103901202B (zh) * | 2014-04-04 | 2015-08-12 | 中国人民解放军成都军区疾病预防控制中心 | 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法 |
| US10925936B2 (en) | 2014-09-03 | 2021-02-23 | Nitto Denko Corporation | Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates |
| EP3189852B1 (en) | 2014-09-03 | 2021-04-07 | Nitto Denko Corporation | Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity |
| US11278616B2 (en) | 2015-08-06 | 2022-03-22 | Nitto Denko Corporation | Immunity induction promoting composition, and vaccine pharmaceutical composition |
| WO2018126060A1 (en) * | 2016-12-28 | 2018-07-05 | Invvax, Inc. | Influenza vaccines |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| IL101639A0 (en) | 1992-04-17 | 1992-12-30 | Yeda Res & Dev | Recombinant influenza vaccines |
| AU3036597A (en) * | 1996-05-21 | 1997-12-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells |
| IL127331A0 (en) * | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
-
1998
- 1998-11-30 IL IL12733198A patent/IL127331A0/xx unknown
-
1999
- 1999-11-28 DK DK10003160.8T patent/DK2204187T3/da active
- 1999-11-28 AT AT10003160T patent/ATE556719T1/de active
- 1999-11-28 BR BR9915811-6A patent/BR9915811A/pt not_active IP Right Cessation
- 1999-11-28 PT PT10003160T patent/PT2204187E/pt unknown
- 1999-11-28 ES ES10003160T patent/ES2389611T3/es not_active Expired - Lifetime
- 1999-11-28 US US09/856,920 patent/US6740325B1/en not_active Expired - Lifetime
- 1999-11-28 CA CA2352454A patent/CA2352454C/en not_active Expired - Lifetime
- 1999-11-28 AU AU14066/00A patent/AU766883B2/en not_active Expired
- 1999-11-28 KR KR1020017006639A patent/KR100703571B1/ko not_active Expired - Lifetime
- 1999-11-28 IL IL14336799A patent/IL143367A0/xx active IP Right Grant
- 1999-11-28 EP EP99972929A patent/EP1135159A2/en not_active Withdrawn
- 1999-11-28 EP EP10003160A patent/EP2204187B1/en not_active Expired - Lifetime
- 1999-11-28 JP JP2000584919A patent/JP2002531415A/ja active Pending
- 1999-11-28 HK HK02102105.6A patent/HK1040620A1/zh unknown
- 1999-11-28 WO PCT/IL1999/000640 patent/WO2000032228A2/en not_active Ceased
- 1999-11-28 NZ NZ511918A patent/NZ511918A/en not_active IP Right Cessation
-
2001
- 2001-05-24 IL IL143367A patent/IL143367A/en not_active IP Right Cessation
-
2004
- 2004-05-17 US US10/846,548 patent/US7192595B2/en not_active Expired - Lifetime
-
2007
- 2007-02-07 US US11/672,429 patent/US7514086B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1135159A2 (en) | 2001-09-26 |
| KR100703571B1 (ko) | 2007-04-05 |
| EP2204187A1 (en) | 2010-07-07 |
| IL143367A0 (en) | 2002-04-21 |
| US6740325B1 (en) | 2004-05-25 |
| US20050002954A1 (en) | 2005-01-06 |
| CA2352454A1 (en) | 2000-06-08 |
| HK1040620A1 (zh) | 2002-06-21 |
| WO2000032228A3 (en) | 2000-10-05 |
| DK2204187T3 (da) | 2012-08-20 |
| JP2002531415A (ja) | 2002-09-24 |
| IL127331A0 (en) | 1999-09-22 |
| US7192595B2 (en) | 2007-03-20 |
| BR9915811A (pt) | 2001-08-21 |
| US20070122424A1 (en) | 2007-05-31 |
| NZ511918A (en) | 2003-08-29 |
| AU766883B2 (en) | 2003-10-23 |
| EP2204187B1 (en) | 2012-05-09 |
| AU1406600A (en) | 2000-06-19 |
| IL143367A (en) | 2006-09-05 |
| US7514086B2 (en) | 2009-04-07 |
| HK1145448A1 (en) | 2011-04-21 |
| ES2389611T3 (es) | 2012-10-29 |
| KR20010089512A (ko) | 2001-10-06 |
| PT2204187E (pt) | 2012-08-10 |
| ATE556719T1 (de) | 2012-05-15 |
| WO2000032228A2 (en) | 2000-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2352454C (en) | Peptide-based vaccine for influenza | |
| Ben-Yedidia et al. | Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection | |
| Eliasson et al. | CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine | |
| Ben-Yedidia et al. | Towards an epitope-based human vaccine for influenza | |
| Mitchell et al. | Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins | |
| Kodihalli et al. | Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective | |
| US10201601B2 (en) | Compositions and methods for increasing immunogenicity of glycoprotein vaccines | |
| Wang et al. | Virus‐Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice | |
| Sawai et al. | Induction of cytotoxic T‐lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin | |
| US12397050B2 (en) | Universal mammalian influenza vaccine | |
| Katz et al. | Recognition of influenza virus hemagglutinin by subtype-specific and cross-reactive proliferative T cells: contribution of HA1 and HA2 polypeptide chains. | |
| Uchida et al. | Application of surface-linked liposomal antigens to the development of vaccines that induce both humoral and cellular immunity | |
| HK1145448B (en) | Human flu vaccine containing four influenza peptides | |
| MXPA01005398A (en) | Peptide-based vaccine for influenza | |
| Arnon et al. | Synthetic recombinant vaccines against viral agents | |
| KR20190137385A (ko) | 저온 적응된 약독화 바이러스를 이용한 유니버설 독감 백신 | |
| Ben-Yedidia et al. | Synthetic peptide-based vaccines against influenza | |
| WO1994022917A1 (en) | Cross-reactive influenza a immunization | |
| Shortridge et al. | Avirulent Avian Influenza Virus as | |
| Arnon et al. | SYNTHETIC RECOMBINANT VACCINE INDUCES ANTI-INFLUENZA LONG-TERM IMMUNITY AND CROSS-STRAIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20191128 |